

# Clinical Outcomes and Predictors of Response for Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: A KASID Prospective Multicenter Cohort Study

**Seung Yong Shin**

Chung-Ang University Hospital

**Soo Jung Park**

Yonsei University

**Young Kim**

Chung-Ang University Hospital

**Jong Pil Im**

Seoul National University Hospital

**Hyo Jong Kim**

Kyung Hee University

**Kang-Moon Lee**

Catholic University of Korea

**Ji Won Kim**

Seoul National University Hospital

**Sung-Ae Jung**

Ewha Womans University Medical Center

**Jun Lee**

Chosun University Hospital

**Sang-Bum Kang**

Catholic University of Korea

**Sung Jae Shin**

Ajou University Hospital

**Eun Sun Kim**

Korea University Medical Center

**You Sun Kim**

Inje University Seoul Paik Hospital

**Tae Oh Kim**

Inje University Haeundae Paik Hospital

**Hyun-Soo Kim**

Chonnam National University Hospital

**Dong Il Park**

Kangbuk Samsung Hospital

**Hyung Kil Kim**

Inha University Hospital

**Eun Soo Kim**

Kyungpook National University Hospital

**Young-Ho Kim**

Samsung Medical Center

**Do Hyun Kim**

AbbVie Ltd.

**Dennis Teng**

AbbVie Pte.Ltd.

**Jong-Hwa Kim**

Chung-Ang University Hospital

**Wonyong Kim**

Chung-Ang University Hospital

**Chang Hwan Choi (✉ [gicch@cau.ac.kr](mailto:gicch@cau.ac.kr))**

Chung-Ang University Hospital

---

**Research Article**

**Keywords:** inflammatory bowel disease, tumor necrosis factor inhibitors, treatment outcome

**Posted Date:** November 25th, 2020

**DOI:** <https://doi.org/10.21203/rs.3.rs-110002/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

A prospective, observational, multicenter study was conducted over 56 weeks in 146 adult patients with moderately to severely active ulcerative colitis (UC) who received adalimumab (ADA) at 17 Korean academic hospitals. Clinical response rates were 52.1% and 37.7% and clinical remission rates were 24.0% and 21.9% at weeks 8 and 56, respectively. Mucosal healing rates were 39.0% and 30.1% at weeks 8 and 56, respectively. Prior use of anti-tumor necrosis factor- $\alpha$  (anti-TNF- $\alpha$ ) did not affect clinical outcomes. The ADA drug level was significantly higher in patients with better outcomes at week 8. In patients with lower endoscopic activity, higher body mass index, and higher serum albumin levels at baseline, the clinical response rate was higher at week 8. In patients with lower Mayo scores and C-reactive protein levels, clinical responses, and mucosal healing at week 8, the clinical response rate was higher at week 56. Serious adverse drug reactions were identified in 2.7% of patients. ADA is effective and safe for induction and maintenance in Korean patients with UC, regardless of prior anti-TNF- $\alpha$  therapy. The ADA drug level is associated with the efficacy of induction therapy. Patients with better short-term outcomes were predictive of those with an improved long-term response

## Introduction

Ulcerative colitis (UC) is a chronic, idiopathic inflammatory bowel disease (IBD) characterized by relapsing abdominal pain and bloody diarrhea with or without mucus.<sup>1</sup> The incidence and prevalence of UC have been reported as high in northern Europe and North America and low in Asian countries.<sup>2-5</sup> However, researchers recently observed an increased number of UC patients in Asian countries including Korea, Japan, China and Taiwan.<sup>6-8</sup> The incidence of UC in Asia has been rising in relation to rapid urbanization and a westernized lifestyle.<sup>9,10</sup> A population-based study performed in Korea showed that the incidence and prevalence of UC have been gradually increasing.<sup>10,11</sup> Furthermore, the genetic and clinical characteristics of IBD patients from Asia and Western countries are slightly different.<sup>12,13</sup>

Adalimumab (ADA) is a fully human immunoglobulin G1 monoclonal antibody directed against tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) that inhibits the activity of the cytokine by blocking the interaction of TNF- $\alpha$  with its p55 and p75 cell surface receptors.<sup>14</sup> In Korea, ADA has been administered to patients with UC since 2013, and a nationwide population-based study showed that 27.6% were treated using ADA among patients received anti-TNF- $\alpha$  therapy.<sup>10</sup>

Till date, little information regarding the clinical outcomes of the use of ADA in the Korean population is available. Most published studies of clinical outcomes in IBD have been conducted on Western patients. Investigating the clinical outcomes of biologic agents in Korean IBD patients will enable a better understanding and optimal management of this condition. Therefore, we conducted a prospective, observational, multicenter study to evaluate the real-world efficacy and safety of ADA and predictors of response in Korean patients with UC.

# Results

## *Primary endpoint*

A total of 146 patients from 17 academic hospitals in Korea were enrolled and included in the analysis.

**Table 1** summarizes the baseline clinical characteristics of the participants.

Clinical response was achieved in 52.1% (76/146) of the patients at week 8 and 37.7% (55/146) of the patients at week 56 (**Fig. 1A**). Clinical response rate at week 56 in week 8 responders was 54.0% (41/76). Clinical response rate was not significantly different between patients who received anti-TNF- $\alpha$  and those who did not (**Fig. 1B, 1C**).

## *Secondary endpoints*

At week 8, 24.0% (35/146) of patients were in clinical remission, and 22.0% (32/146) of patients achieved clinical remission at week 56. Steroid-free clinical remission was achieved in 12.3% (18/146) of patients at week 8 and 21.2% (31/146) of patients at week 56. Mucosal healing was achieved in 39.0% (57/146) of patients at week 8 and 30.1% (44/146) at week 56 (**Fig. 1A**). Rates of clinical remission, steroid-free remission, and mucosal healing were not significantly different between patients who received anti-TNF- $\alpha$  and those who did not (**Fig. 1B, 1C**). Twenty-five patients (17.1%) experienced dose escalation, and 40% and 20% of these achieved clinical response and remission at week 56, respectively.

## *Comparison of clinical characteristics between clinical responders and non-responders*

A comparison of clinical characteristics between clinical responders and non-responders can be found in **Table 2 and 3**. Higher BMI ( $P = 0.034$ ) and serum albumin level ( $P = 0.019$ ), and less severe endoscopic findings ( $P = 0.002$ ) at baseline were associated with clinical response at week 8. Higher baseline BMI ( $P = 0.017$ ), and clinical response ( $P < 0.001$ ) and mucosal healing ( $P = 0.008$ ) at week 8 were associated with clinical response at week 56. Mayo score ( $P = 0.026$ ) and serum CRP level ( $P = 0.035$ ) at week 8 were significantly lower in clinical responders than in non-responders at week 56. In the multivariate analysis, baseline non-severe endoscopic finding (OR 2.951; 95% CI, 1.365–6.382,  $P = 0.006$ ) and clinical response (OR, 10.456; 95% CI, 1.903–57.458,  $P = 0.007$ ) at week 8 were independent predictive factors for clinical responses at week 8 and week 56, respectively (**Table 4**).

## *Exploratory outcomes*

Treatment persistence rates were 88.4% (129/146) at week 8, 71.9% (105/146) at week 24, and 57.5% (84/146) at week 56 (**see Supplementary Fig. S1 online**). Causes of discontinuation can be found as **Supplementary Table S1 online**. Clinical response rates according to the partial Mayo score can be found as **Supplementary Fig. S2 online**.

Mean serum ADA concentration (trough level,  $\mu\text{g/mL}$ ) was significantly higher in patients who achieved clinical response (10.8 vs 8.0,  $P = 0.004$ ), remission (11.7 vs 8.3,  $P = 0.007$ ), and mucosal healing (11.0 vs

8.5,  $P = 0.010$ ) than in those with no clinical response, remission, and mucosal healing at week 8, respectively. Mean serum ADA level was  $7.5 \pm 6.4$  (range 0.1-17.7)  $\mu\text{g/mL}$  in patients who stopped ADA administration because of inadequate response (**Fig. 2**).

Fecal calprotectin and CRP levels significantly improved in patients achieving clinical response and mucosal healing compared with patients without clinical response and mucosal healing at week 8. At week 56, FC levels were maintained at levels similar to those at week 8 in each group (**Fig. 3**).

A total of 246 FC levels were collected at the three points, and the correlation with endoscopic findings was investigated by integrating them. The FC level to predict mucosal healing was 274.7 mg/kg, with a sensitivity of 72.2% and specificity of 71.3% on the receiver operating curve (ROC) curve (area under the curve, 0.771). The predictive level for endoscopic remission (Mayo subscore 0) was 87.9 mg/kg, with a sensitivity of 73.6% and specificity of 73.5% on the ROC curve (area under the curve, 0.774) (**Fig. 4**).

### **Safety**

During the study period, 6.2% (9/146) of patients experienced adverse drug reactions. Serious adverse drug reactions that induced hospital admission were identified in 2.8% (4/146) of patients as follows: pneumonia, pulmonary tuberculosis, renal failure, and abdominal pain. (see **Supplementary Table S2 online**).

## **Discussion**

In this prospective multicenter study, we evaluated the real-world clinical effectiveness of ADA treatment and factors associated with the clinical response in Korean patients with moderately to severely active UC. Our study showed similar or slightly higher rates of clinical response and remission than two previous pivotal studies conducted in Western countries: ULTRA-1 and ULTRA-2 (response rates, 50.4%–54.6%; remission rates, 16.5%–18.5% at week 8 and 30.2%–17.3% at week 52).<sup>14,15</sup> Several studies investigating the real-world efficacy of ADA have been reported worldwide. Although it is difficult to directly compare these results, because each study defined clinical response and remission differently, they show similar trends in outcomes.<sup>16-18</sup> A Japanese real-world study that applied the same definition for clinical response and remission as this study, reported similar outcomes.<sup>16</sup> The mucosal healing rate in our study tended to be lower than that reported in previous Western studies,<sup>17,18</sup> but similar to that reported in a Japanese study.<sup>16</sup> Collectively, ADA was similarly effective for induction and maintenance treatments in Korean patients with active UC who were unresponsive to corticosteroids and/or azathioprine/6-mercaptopurine.

Previous experience with anti-TNF- $\alpha$  therapy was not found to impact the short- or long-term outcomes in our study. Prior anti-TNF- $\alpha$  therapy has been reported to have controversial effects on clinical outcomes of ADA in patients with UC. The ULTRA-2 and ULTRA-3 studies reported better outcomes in patients not treated with anti-TNF- $\alpha$ .<sup>14,19</sup> A retrospective multicenter study in Spain investigated the influence of

previous anti-TNF- $\alpha$  use on the outcomes of ADA maintenance treatment in patients with UC; patients not previously treated with anti-TNF- $\alpha$  had a numerically higher rate of clinical response at week 56 without statistical significance.<sup>20</sup> They had significantly lower probabilities of avoiding colectomy and dose escalation. However, in a previous Hungarian prospective study, response to ADA and need for dose escalation were not associated with previous IFX therapy.<sup>18</sup> A retrospective study performed in Ireland showed a pattern of improved outcomes in patients treated with anti-TNF- $\alpha$  compared with those who were not.<sup>21</sup> Although a note of caution is due in our study because of the relatively small portion of patients treated with anti-TNF- $\alpha$  (n = 36, 24.7%), ADA can be suggested as a beneficial option for Korean patients with moderately to severely active UC treated previously with anti-TNF- $\alpha$  therapy. In addition, the combination therapy with azathioprine/6-mercaptopurine did not affect clinical response rate. This finding is consistent with that of previous studies showing no efficacy-related benefits following immunomodulator/ADA combination therapy.<sup>19,22,23</sup>

In this study, baseline BMI, endoscopic findings, and serum albumin level were associated with clinical response at week 8. At week 56, baseline BMI and clinical response, mucosal healing, CRP level, and Mayo score at week 8 were associated with clinical response. In the multivariate analysis, baseline non-severe endoscopic finding and clinical response at week 8 were independent factors for predicting response at weeks 8 and 52, respectively. Although it was a significant factor only in the univariate analysis, BMI was associated with both short- and long-term response. Previous studies have shown that obese patients tended to have higher risk of nonresponse to biologic agents because of their direct effect on inflammation and modification of pharmacokinetics.<sup>14,24</sup> However, average BMI of both responder and non-responder groups were within the normal range in our study. Relatively higher BMI within the normal range might reflect less severe disease status. CRP level has been suggested as a predictor of poor outcome in UC patients<sup>25</sup> and considered a biomarker of response to IFX induction therapy.<sup>26</sup> Endoscopic finding is also one of the major factors determining the severity and prognosis of UC. In this study, the baseline CRP levels were lower in responders than in non-responders, though without statistical significance. The less severe endoscopic activity was associated with better response to induction therapy of ADA. The findings from this study suggest that ADA therapy may be more effective in moderately active UC than in severely active UC.

Parameters associated with early response such as mucosal healing, clinical response, and CRP level were associated with long-term response. Mucosal healing has been reported to be associated with long-term clinical outcomes<sup>17,27</sup> and suggested as a predictive factor of long-term outcome in Korean UC patients treated with IFX.<sup>28</sup> Early clinical response has also been demonstrated as a predictive factor of better long-term clinical outcomes in several real-world studies.<sup>16,29,30</sup> In Korean patients with moderately to severely active UC, early response is also a positive predictor for long-term clinical response.

During the study period, 25 patients (17.1%) required dose escalation, and 40% and 20% of these regained clinical response and remission, respectively, at week 56. Compared to previous Western studies,

the proportion of patients who experienced dose escalation in our study was relatively small; however, the clinical outcomes are similar to those of these studies.<sup>20,31,32</sup>

Consistent with previous studies on mucosal healing-associated FC levels,<sup>33-35</sup> in this study, FC levels were well correlated with not only patients' clinical outcomes, but also endoscopic activities. The predictive level was 274.8 mg/kg for mucosal healing and 98 mg/kg for endoscopic remission. These novel findings can be used to predict endoscopic activities in UC patients.

Serum ADA concentrations (trough level) at week 8 were associated significantly with clinical outcomes of induction therapy. The ADA concentrations in patients with clinical response or remission, including both UC and Crohn's disease patients, have been reported at relatively lower rates than in previous studies.<sup>36-38</sup> Few studies have been conducted to investigate ADA concentration in patients with UC only. A Belgian study including IFX responders and non-responders showed similar ADA concentrations as those in this study with respect to short-term mucosal healing.<sup>39</sup> The researchers reported that the average ADA concentration of patients with mucosal healing at week 4 was 10.6 µg/mL, which was significantly higher than the concentration in those without mucosal healing (7.4 µg/mL,  $P = 0.014$ ). The higher the drug concentration at week 8 after ADA induction therapy, the better was the expected clinical effect.

No new safety signals were observed in the present study, and the incidence rate was similar to that described in other studies.<sup>17</sup> Any different tendency in safety from the approved label of ADA was not observed. Patients with severe adverse drug reactions including abdominal pain and pulmonary tuberculosis were treated properly, and no deaths were reported.

This was an observational study in routine clinical practice, having certain inherent limitations such as the lack of randomization, leading to potential bias. Moreover, the proportion of subjects who completed the evaluation without any major protocol deviation among the intent-to-treat set was relatively small. Furthermore, anti-ADA antibodies were not evaluated in this study, although it is used in clinical practice in Western countries. However, this study was the first multicenter prospective study to evaluate the efficacy and safety of ADA in Korean UC patients in the real-life clinical setting and explore clinical predictors of response to ADA, including FC and ADA drug levels.

In conclusion, this study showed that ADA is effective and safe for Korean patients with moderately to severely active UC regardless of prior anti-TNF- $\alpha$  therapy. ADA drug level is associated with the efficacy of induction therapy. A good response to induction therapy suggests positive long-term outcomes in Korean patients with moderately to severely active UC.

## Methods

### *Patients*

This prospective, observational, multicenter study was conducted at 17 academic hospitals in Korea from June 2015 to September 2018. The study protocol was approved by the institutional review board at each center (IRB No. C2015020). All patients provided written informed consent. All authors had access to the study data and reviewed and approved the final manuscript.

Eligible patients were aged >18 years and had moderately to severely active UC defined as a Mayo score<sup>40</sup> between 6 to 12, with an endoscopic subscore of at least 2, despite concurrent therapy with 5-aminosalicylic acid, corticosteroids, and azathioprine/6-mercaptopurine. Previous use of anti-TNF- $\alpha$  agents other than ADA was permitted if the patient had discontinued its use owing to primary nonresponse, loss of response, or intolerance to the agent. Exclusion criteria were contraindications for using ADA including malignancy; severe infection such as active tuberculosis, invasive fungal infection, and opportunistic infection; being enrolled in other clinical trials; and pregnancy or breastfeeding. Patients were excluded if they chose to withdraw from the study or if the investigator discontinued ADA because of ethical or practical conflicts.

### ***Baseline assessment***

Baseline assessment performed before administration of ADA included laboratory tests including white blood cells, hemoglobin, platelet, albumin, erythrocyte sedimentation rate, and C-reactive protein (CRP); stool analyses for *Clostridium difficile* infection and fecal calprotectin (FC); and demographic information, including age, sex, body mass index (BMI), family history of IBD, diagnosis date, and extent and duration of UC. The history of conventional medical therapies and prior exposure to anti-TNF- $\alpha$  agents were indicated for each participant. Eligible patients underwent colonoscopy or sigmoidoscopy at each institute before enrollment, and Mayo scores, including endoscopic subscores, were determined. Chest radiograph and the QuantiFERON-TB Gold assay with/without a tuberculin skin test were performed before ADA administration, and latent tuberculosis was treated if present.

### ***Study design***

Patients received subcutaneous injections of ADA: 160 mg at week 0, 80 mg at week 2, and 40 mg every alternate week from week 4. Patients were evaluated at week 0 (baseline), 8, 16, 24, 32, 40, 48, and 56 in accordance with clinical practice. The window period was permitted as  $\pm 1$  week for every visit. All participants underwent safety evaluations  $\leq 30$  days after the last administration of ADA.

Analysis of Mayo scores, including endoscopic subscore, and FC levels and laboratory tests, were performed at week 8 and 56. ADA trough level was evaluated at week 8 and at loss of response, even if ADA dose escalated to weekly injection. Patients with inadequate response to ADA (40 mg every 2 weeks) were permitted to escalate the dosage to 40 mg every week. Patients with inadequate response to dose escalation discontinued the drug based on their physician's judgement. Inadequate response was defined in supplementary section.

### ***Outcomes***

The primary outcomes were clinical response rates at weeks 8 and 56. Clinical response was defined as a decrease in Mayo score from baseline by  $\geq 3$  points and  $\geq 30\%$  with an accompanying decrease in rectal bleeding subscore of  $\geq 1$  point or an absolute rectal bleeding subscore of 0 or 1. Secondary outcomes were proportion of patients with clinical remission, steroid-free remission, and mucosal healing at weeks 8 and 56. Clinical remission was defined as a Mayo score  $\leq 2$  with no individual subscore exceeding 1 point. Steroid-free remission was defined as a clinical remission status with no use of systemic corticosteroids for 12 weeks before the date of investigation. Mucosal healing was defined as an endoscopy subscore of 0 or 1. Clinical response and remission were also assessed using the partial Mayo score. Clinical response was defined as decrease in partial Mayo score from baseline by  $\geq 2$  points and  $\geq 30\%$  with an accompanying decrease in the rectal bleeding subscore of  $\geq 1$  point or an absolute rectal bleeding subscore of 0 or 1. Clinical remission was defined as a partial Mayo score of 0 or 1. In addition, changes in full and partial Mayo scores and FC during the study period were investigated. FC levels were assessed at baseline, week 8, and week 56. The correlation between FC levels and endoscopic findings was investigated regardless of the time points, and cut-off value predicting mucosal healing was also investigated. Predictors of response at weeks 8 and 56 were evaluated based on clinical characteristics at baseline and week 8. Safety evaluation was performed according to the recent version of the Medical Dictionary for Regulatory Activities (MedDRA) v20.0. Physical examination, investigation of vital signs, and laboratory tests were performed from baseline to week 56 and after 30 days from the last administration.

### ***Statistical methods***

Analyses were performed with the intent-to-treat set. Missing or incomplete data were handled using the non-responder imputation method, i.e., patients with missing or incomplete data were assumed to have not achieved the end point. Continuous variables are described with the number of subjects, arithmetic mean, and standard deviation. For categorical variables, the frequency and proportion are presented. For all the statistical tests, two-sided tests were conducted at the 0.05 significance level using the independent or paired *t* test and the chi-square test. To identify factors associated with clinical response at weeks 8 and 56, variables that were significant in univariate analysis were subsequently tested in multivariate logistic regression analysis and expressed as odds ratios (ORs) with 95% confidence intervals. The Kaplan-Meier method was used to evaluate the drug persistence rate. All statistical analyses were performed using SAS (version 9.4; SAS Institute, Inc., Cary, NC, USA).

## **Abbreviations**

ADA=adalimumab; BMI=body mass index; CRP=C-reactive protein; FC=fecal calprotectin; IBD=inflammatory bowel disease; IFX=infliximab; OR=odds ratio; TNF- $\alpha$ =tumor necrosis factor- $\alpha$ ; UC=ulcerative colitis.

## **Declarations**

## Data Availability Statements

The data underlying this article are available in the article and in its online supplementary material

## Acknowledgements

We would like to thank participants and Editage (www.editage.co.kr) for English language editing.

## Author Contributions

Designed the study : C.H.C, S.J.P, J.P.I., H.K.K., J.W.K., K.L., J.L., S.K., S.J.S., Y.S.K., T.O.K., H.K., D.I.P, H.K.K., E.S.K., Y.K., D.H.K., D.T. Data curation : S.Y.S, Y.K, C.H.C. Formal analysis : S.Y.S, Y.K, J.K. W.K.

Visualization: S.Y.S, Y.K, C.H.C. Writing – original draft : S.Y.S, S.J.P. Writing – review & editing : C.H.C., J.P.I., H.K.K., J.W.K., K.L., J.L., S.K., S.J.S., Y.S.K., T.O.K., H.K., D.I.P, H.K.K., E.S.K., Y.K. Approval of final manuscript: all authors.

## Funding

This work was supported by AbbVie Ltd., North Chicago, Illinois, USA and the National Research Foundation of Korea (NRF), Grant/Award Number: NRF-2020R1F1A1075489. AbbVie was responsible for the study design, interpretation of data, reviewing and approving of the publication.

## Competing interests

There are no conflicts of interest to disclose, except for Do Hyun Kim and Dennis Teng. Dennis Teng is an employee of AbbVie, Inc. and may hold stock or stock options. Do Hyun Kim is a former employee of AbbVie, Inc. and may hold stock or stock options.

## References

1. Danese, S. & Fiocchi, C. Ulcerative colitis. *The New England journal of medicine***365**, 1713-1725 (2011).
2. Cosnes, J., Gower-Rousseau, C., Seksik, P. & Cortot, A. Epidemiology and natural history of inflammatory bowel diseases. *Gastroenterology***140**, 1785-1794 (2011).
3. Molodecky, N. A. *et al.* Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. *Gastroenterology***142**, 46-54.e42; quiz e30 (2012).
4. Loftus, C. G. *et al.* Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. *Inflammatory bowel diseases***13**, 254-261 (2007).
5. Yang, S. K., Loftus, E. V., Jr. & Sandborn, W. J. Epidemiology of inflammatory bowel disease in Asia. *Inflammatory bowel diseases***7**, 260-270 (2001).
6. Lakatos, P. L. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? *World journal of gastroenterology***12**, 6102-6108 (2006).

7. Ng, W. K., Wong, S. H. & Ng, S. C. Changing epidemiological trends of inflammatory bowel disease in Asia. *Intestinal research***14**, 111-119 (2016).
8. Yen, H. H. *et al.* Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide populationbased study. *Intestinal research***17**, 54-62 (2019).
9. Prideaux, L., Kamm, M. A., De Cruz, P. P., Chan, F. K. & Ng, S. C. Inflammatory bowel disease in Asia: a systematic review. *Journal of gastroenterology and hepatology***27**, 1266-1280 (2012).
10. Jung, Y. S., Han, M., Kim, W. H., Park, S. & Cheon, J. H. Incidence and clinical outcomes of inflammatory bowel disease in South Korea, 2011-2014: A nationwide population-based study. *Digestive diseases and sciences***62**, 2102-2112 (2017).
11. Park, S. H. *et al.* A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong district of Seoul, Korea in 1986-2015. *Journal of Crohn's & colitis***13**, 1410-1417 (2019).
12. Lee, J. H. *et al.* The prevalence and clinical significance of perinuclear anti-neutrophil cytoplasmic antibody in Korean patients with ulcerative colitis. *Digestive diseases and sciences***55**, 1406-1412 (2010).
13. Park, S. H. *et al.* Clinical features and natural history of ulcerative colitis in Korea. *Inflammatory bowel diseases***13**, 278-283 (2007).
14. Sandborn, W. J. *et al.* Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. *Gastroenterology***142**, 257-265.e251-253 (2012).
15. Reinisch, W. *et al.* Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. *Gut***60**, 780-787 (2011).
16. Suzuki, Y. *et al.* Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. *Journal of gastroenterology***49**, 283-294 (2014).
17. Munoz-Villafranca, C. *et al.* Adalimumab treatment of anti-TNF-naive patients with ulcerative colitis: Deep remission and response factors. *Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver***50**, 812-819 (2018).
18. Balint, A. *et al.* Efficacy and safety of adalimumab in ulcerative colitis refractory to conventional therapy in routine clinical practice. *Journal of Crohn's & colitis***10**, 26-30 (2016).
19. Dulai, P. S., Siegel, C. A., Colombel, J. F., Sandborn, W. J. & Peyrin-Biroulet, L. Systematic review: monotherapy with antitumour necrosis factor alpha agents versus combination therapy with an immunosuppressive for IBD. *Gut***63**, 1843-1853 (2014).
20. Taxonera, C. *et al.* Adalimumab maintenance treatment in ulcerative colitis: outcomes by prior anti-TNF use and efficacy of dose escalation. *Digestive diseases and sciences***62**, 481-490 (2017).
21. Hussey, M. *et al.* Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis. *European journal of gastroenterology & hepatology***28**, 217-221 (2016).
22. Colombel, J. F. *et al.* Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed

- conventional therapy. *Alimentary pharmacology & therapeutics***45**, 50-62 (2017).
23. Matsumoto, T. *et al.* Adalimumab monotherapy and a combination with azathioprine for Crohn's Disease: a prospective, randomized trial. *Journal of Crohn's & colitis***10**, 1259-1266 (2016).
  24. Harper, J. W., Sinanan, M. N. & Zisman, T. L. Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease. *Inflammatory bowel diseases***19**, 2118-2124 (2013).
  25. Henriksen, M. *et al.* C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. results from a prospective population-based study. *Gut***57**, 1518-1523 (2008).
  26. Iwasa, R. *et al.* C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study. *BMC gastroenterology***15**, 103 (2015).
  27. Ardizzone, S. *et al.* Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association***9**, 483-489.e483 (2011).
  28. Lee, K. M. *et al.* Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study. *Journal of gastroenterology and hepatology***28**, 1829-1833 (2013).
  29. Armuzzi, A. *et al.* Adalimumab in active ulcerative colitis: a "real-life" observational study. *Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver***45**, 738-743 (2013).
  30. Taxonera, C. *et al.* Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. *Alimentary pharmacology & therapeutics***33**, 340-348 (2011).
  31. Van de Vondel, S. *et al.* Incidence and predictors of success of adalimumab dose escalation and de-escalation in ulcerative colitis: a real-world Belgian cohort study. *Inflammatory bowel diseases***24**, 1099-1105 (2018).
  32. Wolf, D. *et al.* Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. *Alimentary pharmacology & therapeutics***40**, 486-497 (2014).
  33. Lin, W. C. *et al.* Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients. *World journal of gastroenterology***21**, 13566-13573 (2015).
  34. Lee, S. H. *et al.* Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis. *BMC gastroenterology***17**, 110 (2017).
  35. Kristensen, V., Roseth, A., Ahmad, T., Skar, V. & Moum, B. Fecal calprotectin: a reliable predictor of mucosal healing after treatment for active ulcerative colitis. *Gastroenterology research and practice***2017**, 2098293 (2017).

36. Yarur, A. J. *et al.* Higher adalimumab levels are associated with histologic and endoscopic remission in patients with Crohn's disease and ulcerative colitis. *Inflammatory bowel diseases***22**, 409-415 (2016).
37. Bodini, G. *et al.* Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease. *Scandinavian journal of gastroenterology***51**, 1081-1086 (2016).
38. Paul, S. *et al.* Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis. *Inflammatory bowel diseases***20**, 1288-1295 (2014).
39. Papamichael, K. *et al.* Post-induction adalimumab concentration is associated with short-term mucosal healing in patients with ulcerative colitis. *Journal of Crohn's & colitis***11**, 53-59 (2017).
40. Schroeder, K. W., Tremaine, W. J. & Ilstrup, D. M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. a randomized study. *The New England journal of medicine***317**, 1625-1629 (1987).

## Tables

**Table 1.** Baseline demographic and clinical characteristics of participants

Characteristics	Participants (n = 146)
Age (years)	44.9 ± 14.9
Male sex, no (%)	50 (34.5)
Body weight (kg)	63.2 ± 12.2
BMI (kg/m <sup>2</sup> ) <sup>a</sup>	22.5 ± 3.6
Age at diagnosis (years)	39.4 ± 15.5
Duration of disease (months) <sup>b</sup>	52.8 ± 49.6
Mayo score	8.7 ± 1.4
Endoscopic subscore	2.5 ± 0.5
Disease location	
Proctitis	26 (17.8)
Left-sided colitis	65 (44.5)
Extensive colitis	50 (34.3)
Others	5 (3.4)
Fecal calprotectin (mg/kg)	
Mean ± SD	894.6 ± 630.4
Median	906.0
C-reactive protein (mg/dL)	
Mean ± SD	4.7±11.4
Median	0.9
Albumin (g/dL)	
Mean ± SD	3.8±0.6
Median	3.9
Concomitant medication (Overlapped), n (%)	
5- aminosalicylates	133 (94.3)
Methotrexate	3 (2.1)
Azathioprine/6-Mercaptopurine	79 (56.0)
Cyclosporine/Tacrolimus	0 (0.0)
Systemic corticosteroid	59 (41.8)

20 mg and above (daily dose)	43 (72.9)
Less than 20 mg (daily dose)	33 (55.9)
Prior anti-TNF therapy, n (%)	36 (24.7)
1 medication	34 (94.4)
2 medications and above	2 (5.6)

BMI; body mass index, SD; standard deviation

<sup>a</sup> Data on BMI were available for 144 patients.

<sup>b</sup> Data on duration of disease were available for 80 patients

**Table 2.** Comparison of baseline clinical characteristics between clinical responders and non-responders at week 8 following adalimumab administration

Baseline clinical characteristics	Responder (n = 76)	Non-responder (n = 70)	<i>P</i> value
Age (years)	44.1 ± 14.9	45.9 ± 15.0	0.459
Male sex, no (%)	46 (60.5)	50 (71.4)	0.165
BMI (kg/m <sup>2</sup> )	23.1 ± 3.9	21.8 ± 3.2	0.034
Mayo Clinic score	8.7±1.4	8.8 ± 1.4	0.582
Partial Mayo score	6.2 ± 1.2	6.1 ± 1.3	0.558
Endoscopic finding, n (%)			0.002
Moderate	44 (57.9)	23 (32.9)	
Severe	32 (42.1)	47 (67.1)	
Disease location			0.903
Proctitis	14 (18.4)	12 (17.1)	
Left-sided colitis	33 (43.4)	33 (47.1)	
Extensive colitis	29 (38.2)	25 (35.7)	
Fecal calprotectin (mg/kg), Mean ± SD	853.7 ± 620.9	950.2 ± 645.3	0.414
C-reactive protein (mg/dL), Mean ± SD	3.3 ± 6.7	6.5 ± 15.0	0.109
Albumin (g/dL), Mean ± SD	3.9± 0.6	3.7 ± 0.6	0.019
Concomitant medication ( <i>overlap</i> ), n (%)			
5- aminosalicylates	68 (89.5)	54 (77.1)	0.072
Azathioprine/6-Mercaptopurine	35 (46.1)	35 (50)	0.633
Systemic corticosteroid	25 (32.9)	19(27.1)	0.449

BMI; body mass index, SD; standard deviation

**Table 3.** Comparison of clinical characteristics between clinical responders and non-responders at week 56 following adalimumab administration

Clinical characteristics	Responder (n=55)	Non-responder (n=91)	<i>P value</i>
<b><u>Baseline characteristics</u></b>			
Age (years)	43.8 ± 14.9	45.7 ± 14.9	0.460
Male sex, no (%)	33 (60)	63 (69.2)	0.255
BMI (kg/m <sup>2</sup> ) <sup>a</sup>	23.4 ± 3.9	22.0 ± 3.3	0.017
Mayo Clinic score	9.0 ± 1.3	8.6 ± 1.4	0.096
Partial Mayo score	6.4 ± 1.1	6.0 ± 1.3	0.094
Endoscopic finding, n (%)			0.671
Moderate	24 (43.6)	43 (47.3)	
Severe	31 (56.4)	48 (52.7)	
Disease location			0.304
Proctitis	7 (12.7)	19 (20.9)	
Left-sided colitis	24 (43.6)	42 (46.2)	
Extensive colitis	24 (43.6)	30 (33.0)	
Fecal calprotectin (mg/kg), Mean ± SD	850.4 ± 617.1	920.8 ± 640.9	0.559
C-reactive protein (mg/dL), Mean ± SD	3.1 ± 5.9	5.9 ± 15.0	0.109
Albumin (g/dL), Mean ± SD	3.8 ± 0.6	3.8 ± 0.6	0.546
Concomitant medication ( <i>overlap</i> ), n (%)			
5- aminosalicylates	49 (89.1)	73 (80.2)	0.161
Azathioprine/6-Mercaptopurine	30 (54.5)	40 (44.0)	0.215
Systemic corticosteroid	17 (30.9)	27(29.7)	0.874
<b><u>Characteristics at week 8</u></b>			
Clinical response, n (%)	41 (74.5)	35 (38.5)	<0.001
Mucosal healing, n (%)	29 (52.7)	28 (30.8)	0.008
Mayo score, n (%)	3.2 ± 2.3	4.4 ± 3.1	0.026
Partial Mayo score	1.9 ± 1.6	3.0 ± 2.3	0.001
C-reactive protein (mg/dL), Mean ± SD	0.9 ± 1.3	2.2 ± 4.9	0.035
Fecal calprotectin (mg/kg), Mean ± SD	422.5 ± 505.7	317.7 ± 435.8	0.187

Albumin (g/dL), Mean $\pm$ SD	4.2 $\pm$ 0.5	4.0 $\pm$ 0.5	0.139
Adalimumab trough level ( $\mu$ g/mL)	9.3 $\pm$ 5.0	9.9 $\pm$ 5.4	0.550
Concomitant use of AZA/6-MP	27 (49.1)	31 (34.1)	0.072


BMI; body mass index, SD; standard deviation

**Table 4.** Multivariate analysis for predictive factors of clinical response to adalimumab at weeks 8 and 56

Predictive factors of clinical response at week 8	OR	95% CI	<i>P</i> -value
Baseline			
BMI $\geq$ 23 (kg/m <sup>2</sup> )	1.218	0.578-2.567	0.604
Non-severe endoscopic finding	2.951	1.365-6.382	0.006
Albumin $\geq$ 4.0(g/dL)	1.497	0.697-3.214	0.301
Predictive factors of clinical response at week 56	OR	95% CI	<i>P</i> -value
Week 8			
Clinical response	10.456	1.903-57.458	0.007
Mucosal healing	0.777	0.185-3.260	0.731
Mayo score $\leq$ 3	2.046	0.268-15.641	0.490
Partial Mayo score $\leq$ 2	0.296	0.040-2.189	0.233
C-reactive protein $\leq$ 1 (mg/dL)	1.748	0.479-6.375	0.398


BMI; body mass index, OR; odds ratio, CI; confidence interval

## Figures




**Figure 1**

Clinical response, remission, steroid-free remission, and mucosal healing rates according to the Mayo score at week 8 and 56 (A). Clinical outcomes according to prior anti TNF- $\alpha$  therapy at weeks 8 (B) and 56 (C). Clinical outcomes did not differ whether the patients had experienced anti-TNF therapy or not




**Figure 2**

Serum adalimumab concentration ( $\mu\text{g/mL}$ ) according to clinical outcomes at week 8. Mean serum adalimumab levels were significantly higher in patients who achieved clinical response, remission, and mucosal healing than in those without clinical response, remission, and mucosal healing, respectively, at week 8.



**Figure 3**

Changes in mean fecal calprotectin and c-reactive protein levels from baseline in clinical responders and non-responders at week 8 (A) and in patients with and without mucosal healing at week 8 (B). Fecal calprotectin and c-reactive protein levels significantly improved in patients achieving clinical response and mucosal healing compared with patients without clinical response and mucosal healing, respectively, at week 8. \*P < .05



**Figure 4**

Fecal calprotectin levels according to endoscopic subscore (A), fecal calprotectin level to predict mucosal healing (B) and endoscopic remission (C) on receiver operating characteristic (ROC) curve. Fecal calprotectin levels were well correlated with patients' endoscopic activities. The predictive level was 274.8 mg/kg for mucosal healing and 98 mg/kg for endoscopic remission, respectively.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementarydocuments.docx](#)
- [SupplementaryFigure.pptx](#)